Opportunities and Challenges for Innovative Drugs in China: Strategies for successful reimbursement

ISPOR Europe 2022 -- China's near-universal drug coverage has limitations due to high out-of-pocket costs for patients and poor coverage of innovative, premium-priced medicines. To increase access to high-cost innovative drugs, national drug price negotiations were introduced in 2015. The objective was to describe current opportunities and challenges for innovative drugs in China based on recent evidence from the new reimbursement decision making processes. It was concluded that pharmaceutical companies will need to track NRDL trends, monitor actual decisions by therapeutic areas, develop tailored strategies and demonstrate comprehensive value to achieve market access and reimbursement for innovative drugs in China.